JP Morgan Maintains Overweight on Rocket Pharmaceuticals, Lowers Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph maintains an Overweight rating on Rocket Pharmaceuticals (NASDAQ:RCKT) but lowers the price target from $55 to $50.

February 27, 2024 | 6:25 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan maintains an Overweight rating on Rocket Pharmaceuticals but lowers the price target from $55 to $50.
While the reduction in price target could suggest a tempered outlook, the maintenance of an Overweight rating indicates continued confidence in the company's fundamentals. This mixed signal could lead to neutral short-term price movement as investors digest both the positive and negative aspects of the update.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100